Literature DB >> 22867722

Changes in seroprevalence to hepatitis A in Victoria, Australia: a comparison of three time points.

A E Heywood1, A T Newall, Z Gao, J G Wood, A Breschkin, S Nicholson, H F Gidding, D E Dwyer, G L Gilbert, C R Macintyre.   

Abstract

Serological data provide an important measure of past exposure and immunity to hepatitis A virus (HAV) infection in a population. National serosurveys from developed countries have typically indicated a decline in HAV seroprevalence over time as sanitation levels improve. We examined trends in the seroepidemiology of HAV antibodies in Victoria, Australia, drawing on cross-sectional samples taken at three time points over a 20-year period. Stored sera from 1988 (n=753), 1998 (n=1091), and 2008 (n=791) from persons aged 1-69 years were obtained from the state of Victoria, Australia. The within-year population adjusted results show a significant trend of increasing population HAV seroprevalence over time from 34.3% (95% CI 31.7-36.9) in 1988, to 40.0% (95% CI 37.1-42.8) in 1998 and 55.1% (95% CI 52.1-58.1) in 2008, P<0.0001. A particularly noticeable rise in population seroprevalence was observed between 1998 and 2008 for those aged 5-39 years. The increase in HAV seropositivity over time is in contrast to the declining rates of disease notification in Australia. Based on comparisons with other Australian data, it appears the increase in population seroprevalence over the last two decades is unlikely to be due to endemic transmission of infection. Instead, other factors, including increases in travel to HAV endemic regions, migration to Australia from HAV endemic regions and vaccine uptake are more likely causes. Ongoing monitoring of serological HAV profiles in the population is required to determine future policy direction to prevent increased burden.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22867722     DOI: 10.1016/j.vaccine.2012.07.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  High Prevalence of Symptomatic Hepatitis A Infection in Rural Area of Chaharmahal VA Bakhtiari Province, Iran.

Authors:  Ali Karimi; Seifollah Mortazaei; Mohammad-Taghi Moradi
Journal:  J Clin Diagn Res       Date:  2015-02-01

2.  Prevalence of antibodies against hepatitis A virus among children and adolescents in Germany.

Authors:  A Krumbholz; A Neubert; H Girschick; H I Huppertz; P Kaiser; J Liese; A Streng; T Niehues; J Peters; A Sauerbrey; H Schroten; T Tenenbaum; S Wirth; A Sauerbrei
Journal:  Med Microbiol Immunol       Date:  2013-06-29       Impact factor: 3.402

3.  Ultra-deep sequencing analysis of the hepatitis A virus 5'-untranslated region among cases of the same outbreak from a single source.

Authors:  Shuang Wu; Shingo Nakamoto; Tatsuo Kanda; Xia Jiang; Masato Nakamura; Tatsuo Miyamura; Hiroshi Shirasawa; Nobuyuki Sugiura; Azusa Takahashi-Nakaguchi; Tohru Gonoi; Osamu Yokosuka
Journal:  Int J Med Sci       Date:  2013-12-20       Impact factor: 3.738

4.  Bayesian modelling of a hepatitis A outbreak in men who have sex with men in Sydney, Australia, 1991/1992.

Authors:  X-S Zhang; A Charlett
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

5.  Estimating the critical immunity threshold for preventing hepatitis A outbreaks in men who have sex with men.

Authors:  D G Regan; J G Wood; C Benevent; H Ali; L Watchirs Smith; P W Robertson; M J Ferson; C K Fairley; B Donovan; M G Law
Journal:  Epidemiol Infect       Date:  2015-11-13       Impact factor: 4.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.